Aileron Stock Analysis

ALRN
 Stock
  

USD 2.83  0.06  2.17%   

Aileron Therapeutics price slide over the last few months could raise concerns from institutional investors as the firm is trading at a share price of 2.83 on 3,657 in volume. The company directors and management were not very successful in positioning the firm resources to exploit market volatility in November. However, diversifying your holdings with Aileron Therapeutics or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.21. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Aileron Therapeutics partners.
Please continue to Trending Equities.
  
The Aileron Therapeutics stock analysis report makes it easy to digest most publicly released information about Aileron Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Aileron Stock analysis module also helps to analyze the Aileron Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Aileron Stock Analysis Notes

About 31.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.58. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aileron Therapeutics recorded a loss per share of 0.31. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 11th of November 2022. Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts. Aileron Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. For more info on Aileron Therapeutics please contact Joseph Yanchik at 617 995 0900 or go to https://www.aileronrx.com.

Aileron Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Aileron Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Aileron Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Aileron Therapeutics generated a negative expected return over the last 90 days
Aileron Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (26.16 M) with loss before overhead, payroll, taxes, and interest of (17.01 M).
Aileron Therapeutics currently holds about 32.38 M in cash with (23.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36.
Aileron Therapeutics has a frail financial position based on the latest SEC disclosures

Aileron Therapeutics Upcoming and Recent Events

Earnings reports are used by Aileron Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aileron Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of March 2022
Next Financial Report10th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Aileron Largest EPS Surprises

Earnings surprises can significantly impact Aileron Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-11-12
2020-09-30-0.15-0.130.0213 
2020-05-11
2020-03-31-0.2-0.24-0.0420 
2019-11-07
2019-09-30-0.24-0.28-0.0416 
View All Earnings Estimates

Aileron Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Aileron Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Aileron Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Aileron Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
8th of July 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
29th of June 2022
Other Events
View
16th of June 2022
Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
8th of June 2022
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
7th of June 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
29th of April 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
14th of February 2022
Unclassified Corporate Event
View

Aileron Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 12.58 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aileron Therapeutics's market, we take the total number of its shares issued and multiply it by Aileron Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Aileron Profitablity

Aileron Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Aileron Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Aileron Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Aileron Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Aileron Therapeutics' profitability requires more research than a typical breakdown of Aileron Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(68.42) (73.82) 
Return on Average Equity(84.25) (90.91) 
Return on Invested Capital(0.61) (0.63) 

Management Efficiency

The entity has return on total asset (ROA) of (0.4537) % which means that it has lost $0.4537 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.8126) %, meaning that it created substantial loss on money invested by shareholders. Aileron Therapeutics management efficiency ratios could be used to measure how well aileron therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -73.82. The value of Return on Average Equity is estimated to slide to -90.91. Aileron Therapeutics Current Assets are quite stable at the moment as compared to the past year. The company's current value of Current Assets is estimated at 20.71 Million. Assets Non Current is expected to rise to about 312 K this year, although the value of Total Assets will most likely fall to about 26 M.
Last ReportedProjected for 2022
Book Value per Share 0.49  0.53 
Enterprise Value over EBIT(2.30) (2.48) 
Enterprise Value over EBITDA(1.67) (1.81) 
Price to Book Value 1.16  1.41 
Tangible Assets Book Value per Share 0.55  0.56 
Enterprise Value43.5 M43.8 M
Tangible Asset Value48.5 M42.2 M

Technical Drivers

As of the 1st of December, Aileron Therapeutics shows the risk adjusted performance of (0.05), and Mean Deviation of 4.71. Aileron Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Aileron Therapeutics, which can be compared to its rivals. Please confirm Aileron Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Aileron Therapeutics is priced correctly, providing market reflects its regular price of 2.83 per share. Please also double-check Aileron Therapeutics total risk alpha, which is currently at (0.61) to validate the company can sustain itself at a future point.

Aileron Therapeutics Price Movement Analysis

The output start index for this execution was thirty-three with a total number of output elements of twenty-eight. Aileron Therapeutics Triple Exponential Moving Average indicator shows smoothing effect of Aileron Therapeutics price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

Aileron Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aileron Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aileron Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aileron Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Aileron Therapeutics Predictive Daily Indicators

Aileron Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aileron Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Aileron Therapeutics Forecast Models

Aileron Therapeutics time-series forecasting models is one of many Aileron Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aileron Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Aileron Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aileron Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aileron shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Aileron Therapeutics. By using and applying Aileron Stock analysis, traders can create a robust methodology for identifying Aileron entry and exit points for their positions.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts. Aileron Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.

Current Aileron Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aileron analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aileron analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
2.0Strong Buy1Odds
Aileron Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Aileron analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Aileron stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Aileron Therapeutics, talking to its executives and customers, or listening to Aileron conference calls.
Aileron Analyst Advice Details

Aileron Stock Analysis Indicators

Aileron Therapeutics stock analysis indicators help investors evaluate how Aileron Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aileron Therapeutics shares will generate the highest return on investment. By understating and applying Aileron Therapeutics stock analysis, traders can identify Aileron Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow7639000.00
Common Stock Shares Outstanding1966058.85
Total Stockholder Equity43904000.00
DescriptionAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma Phase 2a clinical trial to treat peripheral T-cell lymphoma Phase I clinical trial for the treatment of acute myeloid leukemia and advanced myelodysplastic syndrome Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patien
Total Cashflows From Investing Activities-35917000.00
Property Plant And Equipment Net280000.00
Retained Earnings-245456000.00
Cash And Short Term Investments45933000.00
Cash3600000.00
CodeALRN
Accounts Payable1210000.00
Net Debt-3438000.00
50 Day M A3.927
Total Current Liabilities4508000.00
Currency CodeUSD
Non Current Assets Total304000.00
Non Currrent Assets Other24000.00
Please continue to Trending Equities. You can also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for analysis

When running Aileron Therapeutics price analysis, check to measure Aileron Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aileron Therapeutics is operating at the current time. Most of Aileron Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aileron Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aileron Therapeutics' price. Additionally, you may evaluate how the addition of Aileron Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Is Aileron Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
12.6 M
Return On Assets
(0.45) 
Return On Equity
(0.81) 
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Aileron Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.